TY - JOUR
T1 - Recessive Genome-wide Meta-analysis Illuminates Genetic Architecture of Type 2 Diabetes
AU - O'Connor, Mark J
AU - Schroeder, Philip
AU - Huerta-Chagoya, Alicia
AU - Cortés-Sánchez, Paula
AU - Bonàs-Guarch, Silvía
AU - Guindo-Martínez, Marta
AU - Cole, Joanne B
AU - Kaur, Varinderpal
AU - Torrents, David
AU - Veerapen, Kumar
AU - Grarup, Niels
AU - Kurki, Mitja
AU - Rundsten, Carsten F
AU - Pedersen, Oluf
AU - Brandslund, Ivan
AU - Linneberg, Allan
AU - Hansen, Torben
AU - Leong, Aaron
AU - Florez, Jose C
AU - Mercader, Josep M
N1 - © 2021 by the American Diabetes Association.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Most genome-wide association studies (GWAS) of complex traits are performed using models with additive allelic effects. Hundreds of loci associated with type 2 diabetes have been identified using this approach. Additive models, however, can miss loci with recessive effects, thereby leaving potentially important genes undiscovered. We conducted the largest GWAS meta-analysis using a recessive model for type 2 diabetes. Our discovery sample included 33,139 case subjects and 279,507 control subjects from 7 European-ancestry cohorts, including the UK Biobank. We identified 51 loci associated with type 2 diabetes, including five variants undetected by prior additive analyses. Two of the five variants had minor allele frequency of <5% and were each associated with more than a doubled risk in homozygous carriers. Using two additional cohorts, FinnGen and a Danish cohort, we replicated three of the variants, including one of the low-frequency variants, rs115018790, which had an odds ratio in homozygous carriers of 2.56 (95% CI 2.05-3.19; P = 1 × 10-16) and a stronger effect in men than in women (for interaction, P = 7 × 10-7). The signal was associated with multiple diabetes-related traits, with homozygous carriers showing a 10% decrease in LDL cholesterol and a 20% increase in triglycerides; colocalization analysis linked this signal to reduced expression of the nearby PELO gene. These results demonstrate that recessive models, when compared with GWAS using the additive approach, can identify novel loci, including large-effect variants with pathophysiological consequences relevant to type 2 diabetes.
AB - Most genome-wide association studies (GWAS) of complex traits are performed using models with additive allelic effects. Hundreds of loci associated with type 2 diabetes have been identified using this approach. Additive models, however, can miss loci with recessive effects, thereby leaving potentially important genes undiscovered. We conducted the largest GWAS meta-analysis using a recessive model for type 2 diabetes. Our discovery sample included 33,139 case subjects and 279,507 control subjects from 7 European-ancestry cohorts, including the UK Biobank. We identified 51 loci associated with type 2 diabetes, including five variants undetected by prior additive analyses. Two of the five variants had minor allele frequency of <5% and were each associated with more than a doubled risk in homozygous carriers. Using two additional cohorts, FinnGen and a Danish cohort, we replicated three of the variants, including one of the low-frequency variants, rs115018790, which had an odds ratio in homozygous carriers of 2.56 (95% CI 2.05-3.19; P = 1 × 10-16) and a stronger effect in men than in women (for interaction, P = 7 × 10-7). The signal was associated with multiple diabetes-related traits, with homozygous carriers showing a 10% decrease in LDL cholesterol and a 20% increase in triglycerides; colocalization analysis linked this signal to reduced expression of the nearby PELO gene. These results demonstrate that recessive models, when compared with GWAS using the additive approach, can identify novel loci, including large-effect variants with pathophysiological consequences relevant to type 2 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=85125212528&partnerID=8YFLogxK
U2 - 10.2337/db21-0545
DO - 10.2337/db21-0545
M3 - Journal article
C2 - 34862199
SN - 0012-1797
VL - 71
SP - 554
EP - 565
JO - Diabetes
JF - Diabetes
IS - 3
ER -